Leuprolide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LEUPROLIDE |
|---|---|
| Type | Drug |
| Aliases | EligardLupronЛейпрорелін |
| Status | reviewed 2026-08-02 | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-DAILYMED-LUPRON-DEPOT-2025 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | GnRH agonist (LHRH agonist) |
|---|---|
| Mechanism | GnRH receptor agonist — initial pituitary stimulation followed by receptor desensitization within 2-4 weeks, suppressing LH/FSH and reducing testicular testosterone production to castrate levels (<50 ng/dL). |
| Typical dosing | Depot formulations are not dose-additive. For example, Lupron Depot is available as 7.5 mg IM every 4 weeks, 22.5 mg IM every 12 weeks, 30 mg IM every 16 weeks, or 45 mg IM every 24 weeks; use the product-specific label. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Workhorse ADT for both mHSPC and mCRPC. Initial flare risk requires anti-androgen overlap — failure to do so can precipitate spinal cord compression in vertebral-metastasis patients.
Used By
Regimens
REG-ADT-ABIRATERONE- ADT + abiraterone + prednisone (continuous)REG-ADT-APALUTAMIDE- ADT + apalutamide (continuous)REG-ADT-DAROLUTAMIDE-DOCETAXEL- ADT + darolutamide + docetaxel (ARASENS triplet)REG-ADT-ENZALUTAMIDE- ADT + enzalutamide (continuous)REG-ADT-LEUPROLIDE- ADT — leuprolide depot (continuous)